- Home
- UCL vs CALC Comparison
UCL vs CALC Comparison
Compare UCL & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCL
- CALC
- Stock Information
- Founded
- UCL 2014
- CALC 2011
- Country
- UCL Hong Kong
- CALC United States
- Employees
- UCL N/A
- CALC N/A
- Industry
- UCL Telecommunications Equipment
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- UCL Consumer Discretionary
- CALC Health Care
- Exchange
- UCL Nasdaq
- CALC Nasdaq
- Market Cap
- UCL 70.6M
- CALC 22.9M
- IPO Year
- UCL 2020
- CALC N/A
- Fundamental
- Price
- UCL $1.86
- CALC $1.64
- Analyst Decision
- UCL
- CALC Strong Buy
- Analyst Count
- UCL 0
- CALC 3
- Target Price
- UCL N/A
- CALC $16.33
- AVG Volume (30 Days)
- UCL 59.7K
- CALC 28.9K
- Earning Date
- UCL 08-13-2025
- CALC 08-11-2025
- Dividend Yield
- UCL N/A
- CALC N/A
- EPS Growth
- UCL N/A
- CALC N/A
- EPS
- UCL 0.09
- CALC N/A
- Revenue
- UCL $92,256,000.00
- CALC N/A
- Revenue This Year
- UCL $6.09
- CALC N/A
- Revenue Next Year
- UCL $7.01
- CALC N/A
- P/E Ratio
- UCL $19.62
- CALC N/A
- Revenue Growth
- UCL 7.65
- CALC N/A
- 52 Week Low
- UCL $0.80
- CALC $1.42
- 52 Week High
- UCL $3.30
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- UCL 55.23
- CALC 49.89
- Support Level
- UCL $1.79
- CALC $1.59
- Resistance Level
- UCL $1.90
- CALC $1.69
- Average True Range (ATR)
- UCL 0.14
- CALC 0.15
- MACD
- UCL -0.03
- CALC 0.01
- Stochastic Oscillator
- UCL 26.19
- CALC 52.26
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.